Tessera Therapeutics
Steve Garbacz joined Tessera in 2021 as the Head of Finance and is responsible for financial reporting, planning, taxes, and treasury.
Steve has more than 25 years of experience in financial management for a range of companies, including Biogen, Epizyme, Spero, and Anika. He has a passion for building scalable financial organizations leveraging new technology and drove successful IPOs at Epizyme and Spero. At Anika, Steve was a key leader in acquiring and integrating two private companies.
Steve has a B.S. in Economics from George Mason University and an M.B.A. in Finance from the Leonard Stern School of Business at New York University.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.